NCT00043186COMPLETEDanonymous

A Randomized, Double-Blind, Placebo-controlled, Multi-dose Phase 2 Study to Determine the Efficacy, Safety and Tolerability of AMG 162 in the Treatment of Postmenopausal Women With Low Bone Mineral Density

Sponsor

Source record

Amgen

Phase

Source record

PHASE2

Modality

AI-normalized

small molecule

Target

AI-normalized

Placebo, Denosumab, Alendronate

Indication / condition

AI-normalized

Low Bone Mineral Density

Intervention

Source record

Placebo, Denosumab, Alendronate

Related intelligence directories

Indication directory: Low Bone Mineral Density Modality directory: small molecule Target directory: Placebo

Source & freshness

Source record

NCT ID

NCT00043186

Original source

ClinicalTrials.gov

Source last updated

Sep 18, 2013

Ingested at

Jun 18, 2026

Internal sync

Jun 18, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT00043186

Title

A Randomized, Double-Blind, Placebo-controlled, Multi-dose Phase 2 Study to Determine the Efficacy, Safety and Tolerability of AMG 162 in the Treatment of Postmenopausal Women With Low Bone Mineral Density

Sponsor

Amgen

Status

COMPLETED

Phase

PHASE2

Condition raw

Low Bone Mineral Density

Condition normalized

Low Bone Mineral Density

Modality raw

small molecule

Modality normalized

small molecule

Target raw

Placebo, Denosumab, Alendronate

Target normalized

Placebo, Denosumab, Alendronate

Interventions

Placebo, Denosumab, Alendronate

Public preview

Source record

To determine the effect of denosumab treatment compared with placebo over 12 months on bone mineral density (BMD) of the lumbar spine in postmenopausal women with low BMD. The clinical hypothesis is that denosumab subcutaneous injections administered every 3 or 6 months for 12 months will significantly increase lumbar spine bone mineral density and will be well tolerated.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Randomized, Double-Blind, Placebo-controlled, Multi-dose Phase 2 Study to Determine the Efficacy, Safety and Tolerability of AMG 162 in the Treatment of Postmenopausal Women With Low Bone Mineral Density

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 18, 2026

NCT ID

NCT00043186

Status

COMPLETED

Phase

PHASE2

Sponsor

Amgen

Executive brief

Investment-Ready Snapshot

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedSep 18, 2013

Internal syncJun 18, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT00043186

Indication

Low Bone Mineral Density

Modality

small molecule

Target

Placebo, Denosumab, Alendronate

Intervention

Placebo, Denosumab, Alendronate

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.